Navigation Links
Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
Date:11/25/2008

RICHMOND, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 4:30 pm (ET) on Tuesday, December 2, 2008 at the Piper Jaffray 20th Annual Health Care Conference in New York. The company will also update the financial community on its latest developments in its therapeutic programs and discuss other business matters at its annual Investor and Analyst Briefing to be held from 4:30 to 6:30 pm ET, on Wednesday, December 3, 2008.

The presentations will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentations will be archived on the Sangamo website for two weeks after the events.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Other therapeutic development programs are focused on cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, co
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
2. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
3. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
4. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
5. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
6. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
7. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
8. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
9. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
10. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
11. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., SHANGHAI, Nov. 30 /PRNewswire-Asia/ -- WuXi ..., biotechnology, and medical-device research and,d...China and the United States,announced that it had...China,2009 list for the fifth consecutive year. Th... in China,s technology, media, and telecommunicati...
(Date:11/27/2009)..., DURHAM, N.C., Nov. 27 Cromoz In...te water-soluble carbon nanotube-based cancer drug...luble carbon nanotubes, which have functional grou...ancer drugs, was developed in partnership with the...carbon nanotubes serves as a drug delivery vehicle...
(Date:11/25/2009)..., BOSTON, Nov. 25 Biotech firm Re...enomic data from the 1918 pandemic through the pre...1 pandemic, today issued its latest biochemical an...ethality of the H1N1 ("Swine Flu") virus has dropp...s,s current outbreak in the spring of 2009 to rest...
(Date:11/25/2009)..., NEW YORK, Nov. 25 Reportlinker.... available in its catalogue: ,, Brazil Bioetha...http://www.reportlinker.com/p0165503/Brazil-Bioeth..., Brazil Bioethanol Market Analysis and Forecas...es detailed analysis and forecasts of the global b...
Breaking Biology Technology:WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10
... at the 7th International Sympo...Sept. 8 ESBATech AG, a leading,developer of antib...e,company has successfully completed its Phase I c...ate, ESBA105, in ophthalmic indications. In,April ...d to evaluate the,safety, tolerability and pharmac...
...ctable HCV RNA levels, following 4 weeks of treatm... Copegus(R) -, - Safety a... with Pegasys plus Cop....,(Nasdaq: VRUS ) announces the preliminary resul...of-concept clinical trial evaluating R7128 1500mg,...
...onsulting announced that it has appointed A.J. Wha... Charlotte, NC (PRWEB) September 8, 2008 -- ww...nsulting] announced that it has appointed A.J. Wha...s Symphony from Wellesley Information Services (WI...ing, and producing national educational conference...
Other Biology Technology:ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 3Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 4Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 5Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 6Symphony Managemnt Consulting Hires New Solutions Director 2
(Date:11/30/2009)... Neurotechnology ( http://www.neur...ometric identification technologies, has released ...e: VeriLook 4.0 Software Development Kit (SDK) f...r large-scale multi-biometric and automated finger...bilities in VeriLook 4.0 provide enhanced facial r...
(Date:11/26/2009)...ries has shown that closing schools in the event o...ificant role in reducing illness transmission. Res...nfectious Diseases compared opportunities for inf...ng that they were reduced when schools are shut. ,... Belgium, led a team of European researchers in us...
(Date:11/25/2009)...may be used to boost resistance to, or slow, the d...Medicine researchers report in a study published i... , Parkinson,s disease is caused by a degenerati...known as the substantia nigra, which is responsibl...dopamine in late-stage Parkinson,s causes symptoms...
Breaking Biology News(10 mins):New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 3School closure could reduce swine flu transmission by 21 percent 2Hormone ghrelin can boost resistance to Parkinson's disease 2Reportlinker Adds Vaccines 2009 3A World Market Analysis Key Players and Critical Trends in a Fast Changing Industry Report 58002 1Reportlinker Adds Vaccines 2009 3A World Market Analysis Key Players and Critical Trends in a Fast Changing Industry Report 58002 2Reportlinker Adds Vaccines 2009 3A World Market Analysis Key Players and Critical Trends in a Fast Changing Industry Report 58002 3Reportlinker Adds Vaccines 2009 3A World Market Analysis Key Players and Critical Trends in a Fast Changing Industry Report 58002 4Reportlinker Adds Vaccines 2009 3A World Market Analysis Key Players and Critical Trends in a Fast Changing Industry Report 58002 5Reportlinker Adds Vaccines 2009 3A World Market Analysis Key Players and Critical Trends in a Fast Changing Industry Report 58002 6Reportlinker Adds Vaccines 2009 3A World Market Analysis Key Players and Critical Trends in a Fast Changing Industry Report 58002 7Reportlinker Adds Vaccines 2009 3A World Market Analysis Key Players and Critical Trends in a Fast Changing Industry Report 58002 8Reportlinker Adds Vaccines 2009 3A World Market Analysis Key Players and Critical Trends in a Fast Changing Industry Report 58002 9Reportlinker Adds Vaccines 2009 3A World Market Analysis Key Players and Critical Trends in a Fast Changing Industry Report 58002 10Reportlinker Adds Vaccines 2009 3A World Market Analysis Key Players and Critical Trends in a Fast Changing Industry Report 58002 11Reportlinker Adds Vaccines 2009 3A World Market Analysis Key Players and Critical Trends in a Fast Changing Industry Report 58002 12Medelis Expands CRO Services to Medical Devices Appoints Dr Inder Makin as VP 14211 1Medelis Expands CRO Services to Medical Devices Appoints Dr Inder Makin as VP 14211 2Medelis Expands CRO Services to Medical Devices Appoints Dr Inder Makin as VP 14211 3FaxBack Announces New HTTPS Fax Platform 57999 1FaxBack Announces New HTTPS Fax Platform 57999 2FaxBack Announces New HTTPS Fax Platform 57999 3
...cientists in Belgium have discovered how to clone ...the laboratory. Their discovery should make it eas...ines from cloned embryos and develop them to provi...annual conference of the European Society of Human...0 June). , Until now, scientists investigating hum...
... method for identifying Bacillus anthracis, the ca...gnostic use by the U.S. Food and Drug Administrati..., was modified by scientists at the U.S. Army Medi...MRIID) to improve its performance and reliability ...rm of the Gamma Phage Assay was first developed by...
...cientists at The Scripps Research Institute have s...em molecule called TLR3, an acronym for Toll-like ...l Science, the protein is described as a large hor...eats (LRRs). , The structure reveals details of T... step toward fully understanding the critical role...
Other Biology News:Scientists succeed in cloning human embryos from eggs matured in the lab 2Scientists succeed in cloning human embryos from eggs matured in the lab 3'Mad cow' proteins successfully detected in blood 2'Mad cow' proteins successfully detected in blood 3Scripps research scientists solve structure of a critical innate immune system protein 2Scripps research scientists solve structure of a critical innate immune system protein 3Scripps research scientists solve structure of a critical innate immune system protein 4
...far-infrared range FT-IR spectrometers give you th...lass. Yet all this comes at an amazingly affordabl...ving a larger and faster mirror closer to the sour...300%,larger solid angle of energy into the interfe...
... measure three fluorescence lifetimespicoseconds t...es. To match the absorption maxima of the amino ac...xcitation source is the powerful NanoLED-17, a pul...han is widely used as a probe of protein structure...
...were designed for full-length gene cloning and req...ed cDNA clone. The first PCR analysis is performed...ains plasmid DNA from 5,000 clones. Having identif... the reaction products, the second PCR analysis is...
...were designed for full-length gene cloning and req...ed cDNA clone. The first PCR analysis is performed...ains plasmid DNA from 5,000 clones. Having identif... the reaction products, the second PCR analysis is...
Biology Products: